Reyes Bernabé
Hospital Universitario Virgen del Rocío · 23 works · 703 citations · h-index 9
Top works
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
- LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
- Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
- KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
- Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
- Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
- Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).
- LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
- Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
- Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk
- Integration of Clinical Information and Imputed Aneuploidy Scores to Enhance Relapse Prediction in Early Stage Lung Cancer Patients.
- Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer.
- Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry
- 138P Faecalibacterium prausnitzii enhances tumor response to perioperative nivolumab and chemotherapy
- 1054P CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
- 1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)
- Therapeutic aggressiveness in the oncological patient at the end of life: Experience in a tertiary hospital.